Ionis Pharmaceuticals, Inc. (NASDAQ:IONS):
Ionis Pharmaceuticals’ CEO, Dr. Stanley Crooke, Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society.
In the market the company is trading up by 5.28 percent from yesterday’s close.
Shares of the company are trading at $36.72 which is slightly above $32.55, the 50 day moving average and which is a tad above the 200 day moving average of $32.38. The 50 day moving average was up by +12.83% and the 200 day average went up by +13.42%.
As of the last earnings report the EPS was $-1.88 and is estimated to be $-1.07 for the current year with 120,919,000 shares now outstanding. Next quarter’s EPS is forecasted at $-0.13 with next year’s EPS anticipated to be $-1.01.
Traders are a little more bullish on shares of Ionis Pharmaceuticals, Inc. of late if you take note of the motion in short interest. The company realized a fall in short interest of -0.09% as of the latest report on September 15, 2016. Short shares decreased from 14,002,218 to 12,673,799 over that timeframe. With short interest at 12,673,799 and short average daily volume at 1,589,909, days to cover is 0.0 and the percentage of shorted shares was 0.10% on September 15.
Brokerage firms have weighed in on the company of late. On May 27, 2016 the stock rating was changed to a “Market Perform” by BMO Capital which was a cut from the previous “Outperform” rating. On May 26 the stock rating was downgraded from “” to “Market Perform” in a statement from Cowen & Company.
On April 7 analysts at BMO Capital released its first research report on the stock giving it an initial rating of “Outperform”. On March 2 JP Morgan made no change to the company rating of “Neutral” and moved down the price target from $68.00 to $64.00.
February 24 investment analysts at Barclays kept the company rating at “Equalweight” but lowered the price expectation to $42.00 from $65.00.